ストックスクリーナーアプリを入手
14.97
6.18%
-0.9258
前日終値:
$15.90
開ける：
$15.815
24時間の取引高:
4.18M
Relative Volume:
0.61
時価総額：
$1.74B
収益：
$52.86M
当期純損益:
$-480.19M
株価収益率:
-3.1929
EPS:
-4.6899
ネットキャッシュフロー:
$-421.82M
1週間 パフォーマンス:
+19.34%
1か月 パフォーマンス:
+58.36%
6か月 パフォーマンス:
+4.76%
1年 パフォーマンス:
+32.13%
1日の値動き範囲:
$14.88
$15.95
1週間の範囲:
$11.93
$15.95
52週間の値動き範囲:
$5.90
$28.25
Intellia Therapeutics Inc Stock (NTLA) Company Profile
名前
Intellia Therapeutics Inc
セクター
電話
857-285-6200
住所
40 ERIE STREET, CAMBRIDGE, MA
NTLA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NTLA
Intellia Therapeutics Inc
|
14.99 | 1.84B | 52.86M | -480.19M | -421.82M | -4.6899 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.42 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.75 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
815.50 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
362.88 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.98 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-12 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2025-11-11 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2025-11-07 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2025-10-28 | ダウングレード | Bernstein | Outperform → Mkt Perform |
| 2025-10-28 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-10-27 | ダウングレード | Guggenheim | Buy → Neutral |
| 2025-10-27 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2025-10-06 | アップグレード | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2025-04-21 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2025-03-05 | 開始されました | H.C. Wainwright | Buy |
| 2025-02-28 | ダウングレード | Goldman | Neutral → Sell |
| 2025-02-28 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2025-01-27 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-23 | ダウングレード | Goldman | Buy → Neutral |
| 2024-02-15 | 開始されました | Wolfe Research | Peer Perform |
| 2023-04-13 | 開始されました | Canaccord Genuity | Buy |
| 2023-03-21 | 開始されました | Bernstein | Outperform |
| 2023-03-14 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2023-02-01 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-01-24 | アップグレード | Citigroup | Sell → Neutral |
| 2023-01-19 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-10-11 | 開始されました | Morgan Stanley | Overweight |
| 2022-09-21 | 開始されました | JP Morgan | Overweight |
| 2022-09-01 | 開始されました | Citigroup | Sell |
| 2022-06-17 | 開始されました | BMO Capital Markets | Market Perform |
| 2022-06-16 | 開始されました | BofA Securities | Buy |
| 2022-04-28 | 開始されました | Credit Suisse | Outperform |
| 2022-02-18 | 開始されました | William Blair | Outperform |
| 2022-02-07 | アップグレード | Oppenheimer | Perform → Outperform |
| 2022-01-31 | 開始されました | Cowen | Outperform |
| 2022-01-07 | 開始されました | Piper Sandler | Overweight |
| 2021-10-05 | 開始されました | Guggenheim | Buy |
| 2021-09-24 | 開始されました | Stifel | Buy |
| 2021-06-28 | 繰り返されました | H.C. Wainwright | Buy |
| 2021-06-11 | 開始されました | H.C. Wainwright | Buy |
| 2021-05-07 | アップグレード | ROTH Capital | Neutral → Buy |
| 2021-05-04 | 開始されました | RBC Capital Mkts | Outperform |
| 2021-03-04 | 開始されました | JMP Securities | Mkt Outperform |
| 2020-12-22 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2020-10-27 | 開始されました | Truist | Buy |
| 2020-10-14 | 開始されました | Wells Fargo | Overweight |
| 2020-09-18 | 開始されました | Goldman | Buy |
| 2020-02-28 | アップグレード | Oppenheimer | Perform → Outperform |
| 2020-02-14 | ダウングレード | Wedbush | Outperform → Neutral |
| 2019-11-01 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2019-07-09 | 開始されました | Robert W. Baird | Outperform |
| 2019-06-10 | 開始されました | ROTH Capital | Neutral |
| 2019-05-03 | アップグレード | Wedbush | Neutral → Outperform |
| 2019-04-12 | 開始されました | Evercore ISI | Outperform |
| 2018-11-02 | ダウングレード | Wedbush | Outperform → Neutral |
| 2018-10-29 | 開始されました | Credit Suisse | Neutral |
| 2018-09-21 | 開始されました | Raymond James | Mkt Perform |
| 2018-05-15 | アップグレード | Chardan Capital Markets | Neutral → Buy |
| 2018-03-08 | 開始されました | JMP Securities | Mkt Outperform |
| 2017-11-01 | 繰り返されました | Jefferies | Buy |
| 2017-06-22 | 再開されました | Jefferies | Buy |
| 2017-03-28 | 開始されました | Chardan Capital Markets | Buy |
| 2016-08-05 | アップグレード | Jefferies | Hold → Buy |
すべてを表示
Intellia Therapeutics Inc (NTLA) 最新ニュース
Risk Check: Can Intellia Therapeutics Inc. grow without dilutionJuly 2025 Trade Ideas & Scalable Portfolio Growth Ideas - mfd.ru
Genome Editing Market Forecast to Reach $23.6 Billion by 2031 Registering 16.6% CAGR: Insights Into Technology and Investment Trends - GlobeNewswire Inc.
Earnings Miss: Will Intellia Therapeutics Inc benefit from government policyJuly 2025 Market Mood & Accurate Buy Signal Alerts - baoquankhu1.vn
Intellia Therapeutics (NASDAQ:NTLA) Shares Up 7.9%Time to Buy? - MarketBeat
Portfolio Update: Does Intellia Therapeutics Inc offer margin of safetyMarket Trend Review & Verified Stock Trade Ideas - baoquankhu1.vn
Is Intellia Therapeutics (NTLA) Pricing Make Sense After Sharp Rebound And DCF Upside Signals - simplywall.st
Intellia Therapeutics: Maintaining A Sell Rating As Platform Risks Escalate - Seeking Alpha
ARK Investment buys 560K shares of Intellia Therapeutics - MSN
Intellia Therapeutics (NTLA) Is Up 6.5% After ARK’s Stock Buying And JPM Pipeline Update – Has The Bull Case Changed? - Yahoo Finance
Is Intellia Therapeutics (NTLA) Pricing Make Sense After Recent 35% Monthly Surge - Yahoo Finance
Assessing Intellia Therapeutics (NTLA) Valuation After Recent Share Price Rebound and Conflicting Fair Value Signals - Yahoo Finance
Treasury Yields: What dividend growth rate does Intellia Therapeutics Inc offerWeekly Trade Recap & High Accuracy Buy Signal Tips - baoquankhu1.vn
Intellia Therapeutics (NASDAQ:NTLA) Downgraded to Sell Rating by Wall Street Zen - MarketBeat
Intellia Therapeutics (NTLA) Stock: Cathie Wood Continues Three-Day Buying Streak - MEXC
Cathie Wood’s ARK Made Just One Buy Last Session — And It’s A Biotech Stock Up Nearly 30% YTD - Stocktwits
Intellia Therapeutics (NTLA) Stock: Cathie Wood’s ARK Buys Third Day Running - Blockonomi
Sumitomo Mitsui Trust Group Inc. Sells 316,409 Shares of Intellia Therapeutics, Inc. $NTLA - MarketBeat
Cathie Wood’s ARK made just one buy last session — and it’s a biotech stock up nearly 30% YTD - MSN
A Look At Intellia Therapeutics (NTLA) Valuation After ARK’s Added Stake And J.P. Morgan Conference Spotlight - Sahm
Cathie Wood’s ARK adds to Intellia stock holdings on January 15 By Investing.com - Investing.com South Africa
ARK Investment Increases Stake in Intellia Therapeutics (NTLA) - GuruFocus
Cathie Wood’s ARK adds to Intellia stock holdings on January 15 - Investing.com India
ARK Invest Acquires 56,769 Shares of Intellia, Stock Rises 2% - Intellectia AI
JPM26: Intellia Therapeutics hopeful on CRISPR safety despite patient death - Yahoo Finance
Intellia Therapeutics (NTLA) Is Up 20.7% After FDA Halts MAGNITUDE ATTR-CM Trial Over Safety EventHas The Bull Case Changed? - Sahm
Assessing Intellia Therapeutics (NTLA) Valuation After FDA Clinical Hold On Lead Gene Editing Trial - Sahm
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
Intellia Therapeutics (NASDAQ:NTLA) Best Nasdaq Stocks Clinical Innovation - Kalkine Media
Intellia Therapeutics, Inc. (NTLA) Recently Broke Out Above the 200-Day Moving Average - Yahoo Finance
SG Americas Securities LLC Acquires 92,485 Shares of Intellia Therapeutics, Inc. $NTLA - MarketBeat
cathie wood’s ARK stock buys INTELLIA, continues trend By Investing.com - Investing.com Nigeria
cathie wood’s ARK stock buys INTELLIA, continues trend - Investing.com
Intellia Therapeutics (NASDAQ:NTLA) Trading Up 6.9%Still a Buy? - MarketBeat
cathie wood’s ARK stock trades highlight intellia, personalis buys By Investing.com - Investing.com Australia
cathie wood’s ARK stock trades highlight intellia, personalis buys - Investing.com
Analysts Are Bullish on Top Healthcare Stocks: Intellia Therapeutics (NTLA), Roche Holding AG (RHHVF) - The Globe and Mail
Intellia CEO Sells $314K in Stock While Holding Over 1 Million Shares - sharewise.com
Fred Cohen Buys 303% More Intellia Therapeutics Shares - Yahoo Finance
Intellia Therapeutics (NASDAQ:NTLA) Upgraded at Wall Street Zen - MarketBeat
Cathie Wood’s ARK ETF Buys Intellia, Personalised Stock; Sells Illumina By Investing.com - Investing.com Canada
Cathie Wood’s ARK ETF Buys Intellia, Personalised Stock; Sells Illumina - Investing.com
Intellia Updates Investors on Nex-Z Trial Safety Hold - TipRanks
Intellia Therapeutics, Inc. Updates on Clinical Trials and Regulatory Plans - TradingView — Track All Markets
Why Intellia Therapeutics Inc. (38I) stock fits value portfoliosMarket Movement Recap & AI Optimized Trade Strategies - ulpravda.ru
CEO Change: Is Intellia Therapeutics Inc. stock a defensive play in 2025Wall Street Watch & Safe Capital Allocation Plans - ulpravda.ru
How Intellia Therapeutics Inc. stock benefits from global expansion2025 Earnings Surprises & Safe Swing Trade Setups - ulpravda.ru
Buyback Watch: Can Intellia Therapeutics Inc. stock beat market expectations this quarterWeekly Trend Report & Free Long-Term Investment Growth Plans - ulpravda.ru
Intellia Therapeutics (NASDAQ:NTLA) Shares Gap UpTime to Buy? - MarketBeat
Gene Editing Tools Market to Reach US$ 1,700.05 million by 2033 | - openPR.com
Insider Buying: Fred Cohen Acquires 150,000 Shares of Intellia T - GuruFocus
Intellia Therapeutics (NASDAQ:NTLA) CEO John Leonard Sells 34,146 Shares of Stock - MarketBeat
Intellia Therapeutics Inc (NTLA) 財務データ
収益
当期純利益
現金流量
EPS
3.31%
2.06%
大文字化:
|
ボリューム (24 時間):